Personal information

Emails & domains

Verified email addresses

Verified email domains

Other IDs

ResearcherID: F-4794-2013
ResearcherID: F-4794-2013
SciProfiles: 580746

Biography

Mark De Ridder graduated at the medical school of the Vrije Universiteit Brussel (VUB) with maxima cum lauda in 1998. He combined his training in Radiotherapy and Oncology with a doctoral fellowship (FWO-Vlaanderen) and defended his PhD “Hypoxic tumor cell radiosensitization through nitric oxide synthase: role of the NF-kB signalling pathway” in 2005. He was nominated professor of Oncology and Cancer Biology at the VUB in 2008 and head of the Radiotherapy department of the UZ Brussel in 2010. Mark De Ridder is also the coordinator of the Spearhead Strategic Research Program “Societal Benefit of Markerless Stereotactic Body Radiotherapy: a Statistical Support based on Quantitative Imaging”.

Activities

Collapse all

Employment (1)

Universitair Ziekenhuis Brussel: Brussels, BE

2010 to present | Head Of Department (Radiotherapie)
Employment
Source: Self-asserted source
Mark De Ridder

Funding (40)

Advanced imaging for better decision-taking in colorectal cancer: AdvantageCRC

2024 to 2028 | Grant
Kom op tegen Kanker (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Quantifying the impact of Covid-19 on non-Covid19 hospital care (Quantico)

2022 to 2026 | Grant
Wetenschappelijk Fonds Willy Gepts, UZ Brussel (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Targeting the redox homeostasis: A promising strategy to improve radiosensitivity of colorectal cancer (PhD beurs Lisa Kerkhove)

Source: Self-asserted source
Mark De Ridder

Uncovering the daily experiences of people with advanced cancer: adaptation and feasibility of the experience sampling method

2020 to 2024 | Grant
Fonds Wetenschappelijk Onderzoek (FWO) (Brussels, BE)
URL: https://researchportal.vub.be/en/publications/uncovering-the-daily-experiences-of-people-living-with-advanced-c
Source: Self-asserted source
Mark De Ridder

RESET-Living: een nazorgtraject op maat voor een nieuwe start na een primaire kankerbehandeling

Source: Self-asserted source
Mark De Ridder

RESTORE: REalistic forecaSTing, cOntrol and pREparedness for coming COVID-19 waves

2020 to 2021 | Grant
Fonds Wetenschappelijk Onderzoek (FWO) (Brussels, BE)
URL: https://researchportal.vub.be/en/projects/restore-realistic-forecasting-control-and-preparedness-for-coming
Source: Self-asserted source
Mark De Ridder

Covid-19 modelling

2020 to 2020 | Grant
Vrije Universiteit Brussel (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Clinical Consulting Services in Stereotactic Radiotherapy

2019 to 2024 | Grant
Brainlab AG (München, DE)
Source: Self-asserted source
Mark De Ridder

SRP-Onderzoekszwaartepunt: Social Benefit of Markerless Stereotactic Body Radiotherapy: a Statistical Support Based on Quantitative Imaging

Source: Self-asserted source
Mark De Ridder

A randomized phase II clinical trial in NSCLC combining SBRT and I.V. anti-PD-1 with or without I.T. anti-CTLA-4/anti-PD-L1 plus CD1c+ myDC

2019 to 2022 | Grant
Fonds Wetenschappelijk Onderzoek (FWO), TBM (Brussels, BE)
URL: https://researchportal.vub.be/en/projects/a-randomized-phase-ii-clinical-trial-in-nsclc-combining-sbrt-and-
Source: Self-asserted source
Mark De Ridder

Quality indicators for palliative care in the Flemish nursing homes

Source: Self-asserted source
Mark De Ridder

Phase II trial of metformin combined with preoperative chemoradiation for rectal cancer: towards an organ preserving approach.

2017 to 2021 | Grant
Kom op tegen Kanker (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Tumor radioimmunotherapy intesified by the anti-arthritic drug auranofin combined with the CD122-biased IL-2/S4B6 immunocomplex (PhD beurs Hui Wang)

Source: Self-asserted source
Mark De Ridder

Myeloid-derived suppressor cells as a novel therapeutic target in colorectal cancer (afwerker Inès Dufait)

Source: Self-asserted source
Mark De Ridder

Towards personalized radiotherapy of high-risk stage II/III rectal cancer: HSP90 profiling and targeting as a basis for hyperthermic radiosensitization

2015 to 2018 | Grant
Stichting tegen Kanker (Brussels, BE)
URL: https://www.kanker.be/project/team-van-professor-mark-de-ridder
Source: Self-asserted source
Mark De Ridder

Image-Guided Radiotherapy

2015 to 2016 | Grant
Accuray (United States) (Sunnyvale, US)
Source: Self-asserted source
Mark De Ridder

SRP-Groeifinanciering: Translating biological tumor signatures into ,image-guided radiotherapy: towards personalized treatments in rectal and lung cancer

Source: Self-asserted source
Mark De Ridder

Hypofractionated radiotherapy as a novel approach to restrict the immunosuppressive tumor microenvironment linked to myeloid-derived suppressor cells.

2014 to 2018 | Grant
Reliable Cancer Therapies + Sonofi Aventis (Germany) (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Myeloid-derived suppressor cells as a novel therapeutic target in colorectal cancer

2014 to 2018 | Grant
Agentschap voor Innovatie door Wetenschap en Technologie (Brussels, BE)
URL: https://researchportal.vub.be/en/projects/myeloid-derived-suppressor-cells-as-a-novel-therapeutic-target-in
Source: Self-asserted source
Mark De Ridder

CSC Scholarship voor Hui Wang

2014 to 2016 | Grant
CSC-VUB Joint Scholarship Programme (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Patient-tailored radiotherapy in medically inoperable rectal cancer: molecular and immune profiling of chemoradioresponse

2013 to 2017 | Grant
Vlaamse Liga tegen Kanker (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Translational research on hypoxia and biomarkers

2013 to 2014 | Grant
Accuray (United States) (Sunnyvale, US)
Source: Self-asserted source
Mark De Ridder

Randomized Phase II study evaluating patient satisfaction during respiratory-synchronized radiation for non-small cell lung cancer

2013 to 2013 | Grant
Wetenschappelijk Fonds Willy Gepts, UZ Brussel (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Arginase as a predictive biomarker and molecular target in chemo/radiotherapy of metastatic colorectal cancer

2012 to 2016 | Grant
Vlaamse Liga tegen Kanker (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Leerstoel: Oncology-Respiratory Chair

2012 to 2013 | Grant
Astra Zeneca (Dilbeek, BE)
Source: Self-asserted source
Mark De Ridder

Biologically Modulated Radiotherapy for Locally Advanced Pancreatic Cancer on the VERO-SBRT system

2012 to 2012 | Grant
Wetenschappelijk Fonds Willy Gepts, UZ Brussel (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Non-invasive mapping of tumor hypoxia for biologically modulated radiotherapy in patients with locally advanced head-and-neck cancer

2012 to 2012 | Grant
Wetenschappelijk Fonds Willy Gepts (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

The role of myeloid-derived suppressor cells in the radioresponse of colorectal cancer (PhD beurs Heng Jiang)

2011 to 2012 | Grant
Vlaamse Liga tegen Kanker (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Randomized trial of preoperative radiotherapy with an integrated simultaneous boost compared to chemoradiotherapy for T3-4 rectal cancer

2010 to 2014 | Grant
Reliable Cancer Therapies + Accuray, Inc. + Wetenschappelijk Fonds Willy Gepts, UZ Brussel (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Tumor radiosensitization by expanded T lymphocytes: NO and CO as molecular determinants of radioresponse through INF-γ signalling pathway

2010 to 2013 | Grant
Fonds Wetenschappelijk Onderzoek (FWO) (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Patient tailored treatment for patients with rectal cancer

2009 to 2011 | Grant
Federal Government, Belgium (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Treatment of cervical cancer by chemoradiation combined with normobaric oxygen inhalation and isosorbide dinitrate

2009 to 2010 | Grant
Cycle for Life, Roche (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Development, validation and clinical implementation of a new concept for high-precision image-guided radiotherapy: the VERO System

2008 to 2014 | Grant
Fonds Wetenschappelijk Onderzoek (FWO) (Brussels, BE)
URL: https://researchportal.vub.be/en/projects/development-validation-and-clinical-implementation-of-a-new-conce
Source: Self-asserted source
Mark De Ridder

CSC Scholarship voor Heng Jiang

2008 to 2011 | Grant
CSC-VUB Joint Scholarship Programme (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Image-Guided Radiotherapy for Rectal Cancer

2007 to 2007 | Grant
Educational grant from Pfizer (Puurs-Sint-Amands, BE)
Source: Self-asserted source
Mark De Ridder

Preoperative radiotherapy of rectal cancer by Helical Tomotherapy: prognostic significance of iNOS, CD16 and CD68 molecular markers

Source: Self-asserted source
Mark De Ridder

Preoperative significance of iNOS; CD16+ and CD68+ molecular markers in the response of rectal cancer to preoperative radiotherapy

2006 to 2006 | Grant
Wetenschappelijk Fonds Willy Gepts, UZ Brussel (Brussels, BE)
Source: Self-asserted source
Mark De Ridder

Radiosensibilisering van tumorcellen door stikstofmonoxide : iNOS en NF-kB als effector en regulerende determinanten van bestralingsgevoeligheid in chronische hypoxie.

2001-10-01 to 2005-09-30 | Grant
Research Foundation - Flanders (Brussels, BE)
URL: https://app.dimensions.ai/details/grant/grant.8490651
GRANT_NUMBER:

1123802N
Source: Self-asserted source
Mark De Ridder via DimensionsWizard

Clinical Consulting Services in Stereotactic Radiotherapy

Grant
Brainlab AG (München, DE)
Source: Self-asserted source
Mark De Ridder

Clinical Consulting Services in Stereotactic Radiotherapy

Grant
Brainlab AG (München, DE)
Source: Self-asserted source
Mark De Ridder

Peer review (22 reviews for 7 publications/grants)

Review activity for Acta oncologica (1)
Review activity for Cancer letters. (1)
Review activity for International journal of radiation oncology, biology, physics. (3)
Review activity for Medical physics. (1)
Review activity for Nature communications (1)
Review activity for Radiotherapy and oncology. (7)
Review activity for Radiotherapy and oncology. (8)
How many people are using ORCID?